Saturn V Capital Management portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Saturn V Capital Management reported a $697M portfolio of 23 positions to the SEC as of the end of Q2 2026. Its largest positions are AMLX, ALMS, ABVX. During the quarter it opened Trevi Therapeutics and Sagimet Biosciences and exited Cogent Biosciences.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Saturn V Capital Management has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Stake reported in the company · event of Jun 30, 2026 · filed Aug 12, 2026 · filing ↗
What changed this quarter
22 positions with a change (3 new, 12 added to, 6 trimmed, 1 sold). 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Cogent Biosciences−3.5 ppof portfolioSold out4.4% → —
- Trevi Therapeutics+2.8 ppof portfolioNew— → 2.8%
- Sagimet Biosciences+1.6 ppof portfolioNew— → 1.6%
- Immix Biopharma+26%more sharesIncreased6.1% → 6.9%
- Ovid Therapeutics−84%fewer sharesReduced1.7% → 0.3%
- Celcuity+31%more sharesIncreased5.8% → 5.6%
- Alumis−9.0%fewer sharesReduced12.8% → 11.8%
- Zura Bio+184%more sharesIncreased0.8% → 1.8%
- Vir Biotechnology+1.1 ppof portfolioNew— → 1.1%
- Disc Medicine+17%more sharesIncreased5.2% → 5.5%
- Amylyx Pharmaceuticals+6.3%more sharesIncreased10.9% → 11.9%
- Candel Therapeutics+14%more sharesIncreased2.6% → 4.9%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Amylyx PharmaceuticalsAMLX11.9%
- AlumisALMS11.8%
- AbivaxABVX9.9%
- VaxcytePCVX7.1%
- Immix BiopharmaIMMX6.9%
- PharvarisPHVS6.5%
- Jazz PharmaceuticalsJAZZ5.6%
- CelcuityCELC5.6%
- Disc MedicineIRON5.5%
- Candel TherapeuticsCADL4.9%
- X4 PharmaceuticalsXFOR4.7%
- Monopar TherapeuticsMNPR4.1%
- Dyne TherapeuticsDYN3.4%
- Trevi TherapeuticsTRVI2.8%
- Zura BioZURA1.8%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 23
Q2 2026: 76%
Q2 2026: 10.5%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Aug 4, 2026 (high confidence).
The data, as reported: SATURN V CAPITAL MANAGEMENT LP (CRD 316649): 7.B private funds: 3 hedge (gross assets $793M); 5.D assets by client type: pooled vehicles 100% (of $793M)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- BwcpInvestment firm · $700M
- Keywise Capital Management (hk)Investment firm · $694M
- 12th Street Asset ManagementInvestment firm · $702M
- Rivermont Capital ManagementInvestment firm · $705M
- HMI Capital ManagementInvestment firm · $686M
- MAK Capital OneInvestment firm · $714M